Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-005129-18-IT (EUCTR)	08/01/2019	26/03/2018	Clinical trial to evaluate the effectiveness and safety of IFN beta-1a (IFN beta-1a), injected once a week via intramuscolar (i.m.), and glatiramer-acetate (GA) in children/adolescent patients with multiple sclerosis.	Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of interferon beta-1a (IFN-beta-1a) weekly i.m. and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis.	Relapsing-remitting multiple sclerosis with paediatric onset MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Copaxone 40 mg/ml solution for injection, pre-filled syringe INN or Proposed INN: Glatiramer Acetate Other descriptive name: GLATIRAMER ACETATE Trade Name: AVONEX 30 µg/0,5 ml solution for injection INN or Proposed INN: Interferon beta -1a Other descriptive name: INTERFERON BETA -1A	Università degli Studi Aldo Moro	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	142	Phase 3	Italy
2	NCT03387046 (ClinicalTrials.gov)	March 26, 2018	22/12/2017	A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)	Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)	Multiple Sclerosis, Relapsing-Remitting	Dietary Supplement: D-aspartate;Drug: Placebo;Biological: IFN beta-1a;Drug: Methylprednisolone	Merck KGaA, Darmstadt, Germany	NULL	Terminated	18 Years	55 Years	All	7	Phase 2	Italy;Germany
3	EUCTR2006-003037-32-ES (EUCTR)	09/02/2007	10/03/2010	Estudio en fase IIIb, multicéntrico, comparado con grupo de control, doble ciego, aleatorizado y de dos brazos, con evaluaciones mensuales por resonancia magnética y biomarcadores para evaluar la eficacia, la seguridad y la tolerabilidad de Rebif New Formulation (IFN beta-1a) en pacientes con esclerosis múltiple remitente-recurrente.A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation)	Estudio en fase IIIb, multicéntrico, comparado con grupo de control, doble ciego, aleatorizado y de dos brazos, con evaluaciones mensuales por resonancia magnética y biomarcadores para evaluar la eficacia, la seguridad y la tolerabilidad de Rebif New Formulation (IFN beta-1a) en pacientes con esclerosis múltiple remitente-recurrente.A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis. - IMPROVE (Investigating MRI Parameters with Rebif® imprOVEd formulation)	Relapsing remitting Multiple Sclerosis MedDRA version: 9.0;Level: PT;Classification code 10063399	Trade Name: Rebif Product Name: Interferon beta -1a FBS-free/HSA-free, RNF Product Code: Not applicable INN or Proposed INN: Interferon-beta 1a Other descriptive name: Not applicable	Merck Serono International SA	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 3	Estonia;Spain;Lithuania;Germany;Italy
4	NCT00428584 (ClinicalTrials.gov)	December 2006	29/1/2007	RNF and Betaseron® Tolerability Study	A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension	Relapsing Remitting Multiple Sclerosis (RRMS)	Drug: New Formulation of rebif - human interferon beta-1a;Drug: Interferon beta -1b	EMD Serono	Pfizer	Completed	18 Years	60 Years	All	129	Phase 3	United States
5	NCT00441103 (ClinicalTrials.gov)	December 2006	26/2/2007	A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis	A Two-arm, Randomized, Double-blind, Control Group-compared, Multicenter, Phase IIIb Study With Monthly MRI and Biomarker Assessments to Evaluate the Efficacy, Safety, and Tolerability of Rebif® New Formulation (IFN Beta-1a) in Subjects With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Rebif ® New Formulation (IFN-beta-1a, RNF);Drug: Placebo	Merck KGaA	NULL	Completed	18 Years	60 Years	All	180	Phase 3	Canada;Germany;Italy;Russian Federation;Spain;Switzerland
6	NCT00223301 (ClinicalTrials.gov)	July 2004	19/9/2005	Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis	A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (cellcept)	University of Texas Southwestern Medical Center	Roche Pharma AG;Biogen Idec	Completed	21 Years	45 Years	Both	24	Phase 2/Phase 3	United States

先頭へ